scout

Harry P. Erba, MD, PhD, Duke University School of Medicine

Articles by Harry P. Erba, MD, PhD, Duke University School of Medicine

The Role of Venetoclax for Treatment of AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center ,Mark Levis, MD, PhD, Johns Hopkins University School of Medicine ,Daniel Pollyea, MD, MS, University of Colorado Denver,Vinod Pullarkat, MD, City of Hope Medical Center

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.

Future Treatment Landscape of AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

Maintenance Therapy Post-Transplant in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Alexander E. Perl, MD, University of Pennsylvania,Eunice Wang, MD, Roswell Park Comprehensive Cancer Center,Adam Bagg, MD, University of Pennsylvania,Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.

Latest Updated Articles